2026 Global: Asthma And Copd Drug Market -Competitive Review (2032) report
Description
The 2026 Global: Asthma And Copd Drug Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for asthma and copd drug market by geography and historical trend. The scope of the report extends to sizing of the asthma and copd drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceutical Industries dominate the asthma and COPD drug market as leading players with extensive portfolios and strong market shares. These companies, alongside Merck, Sanofi, Roche, Pfizer, and Chiesi Farmaceutici, represent the top ten based on consistent mentions across industry reports analyzing revenues, pipelines, and therapeutic innovations from 2020 to 2030. GSK leads with blockbuster products like Trelegy Ellipta, a triple-combination inhaler for COPD and asthma maintenance, generating $3.45 billion in 2024 sales and poised for further growth through guideline endorsements and global uptake. AstraZeneca advances combination therapies and biologics, while Boehringer Ingelheim excels in bronchodilators like Spiriva, capturing significant North American revenue amid rising R&D investments. Novartis bolsters its position via Xolair for allergic asthma ($4.45 billion in 2024) and acquisitions expanding inhalable drugs for both conditions. Teva focuses on generics and affordable inhalers, enhancing accessibility in high-prevalence regions.
Merck, Sanofi, Roche, and Pfizer follow as pivotal contributors, leveraging biologics and strategic expansions to address type 2 inflammation and exacerbations. Merck offers inhaled corticosteroids and combination therapies integral to preventive care, while Sanofi pioneers Dupixent (dupilumab) for moderate-to-severe asthma, with rilzabrutinib showing phase 2 efficacy in reducing symptom events. Roche, co-marketing Xolair with Novartis, reported $3.7 billion in 2024 respiratory revenues from asthma and COPD treatments, underscoring biologics' rising role. Pfizer diversifies through anti-inflammatory drugs and partnerships, complementing its broader immunology pipeline amid market growth projected beyond $16 billion by 2032. Chiesi Farmaceutici specializes in specialized inhalers and therapies for severe cases, gaining traction in Europe and emerging markets via innovative delivery systems. These firms drive competition through pipelines targeting eosinophilic COPD and biologics underserved historically by small molecules.
Market leadership hinges on revenue forecasts, M&A activity, and pipeline advancements amid drivers like prevalence increases and biologic shifts. From 2020-2030, top players like GSK and Novartis forecast robust growth via products like depemokimab and Sandoz generics, while acquisitions—such as Sanofi's partnerships and BMS's immunology expansions—signal consolidation. Challenges include pricing pressures and generics, yet opportunities in digital health (e.g., Abbott's Bigfoot integration) and novel modalities like ENaC inhibitors position them for outperformance. Overall, these ten companies control key segments—bronchodilators, monoclonal antibodies, and combinations—fueling a market responsive to R&D and regulatory approvals.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for asthma and copd drug market by geography and historical trend. The scope of the report extends to sizing of the asthma and copd drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceutical Industries dominate the asthma and COPD drug market as leading players with extensive portfolios and strong market shares. These companies, alongside Merck, Sanofi, Roche, Pfizer, and Chiesi Farmaceutici, represent the top ten based on consistent mentions across industry reports analyzing revenues, pipelines, and therapeutic innovations from 2020 to 2030. GSK leads with blockbuster products like Trelegy Ellipta, a triple-combination inhaler for COPD and asthma maintenance, generating $3.45 billion in 2024 sales and poised for further growth through guideline endorsements and global uptake. AstraZeneca advances combination therapies and biologics, while Boehringer Ingelheim excels in bronchodilators like Spiriva, capturing significant North American revenue amid rising R&D investments. Novartis bolsters its position via Xolair for allergic asthma ($4.45 billion in 2024) and acquisitions expanding inhalable drugs for both conditions. Teva focuses on generics and affordable inhalers, enhancing accessibility in high-prevalence regions.
Merck, Sanofi, Roche, and Pfizer follow as pivotal contributors, leveraging biologics and strategic expansions to address type 2 inflammation and exacerbations. Merck offers inhaled corticosteroids and combination therapies integral to preventive care, while Sanofi pioneers Dupixent (dupilumab) for moderate-to-severe asthma, with rilzabrutinib showing phase 2 efficacy in reducing symptom events. Roche, co-marketing Xolair with Novartis, reported $3.7 billion in 2024 respiratory revenues from asthma and COPD treatments, underscoring biologics' rising role. Pfizer diversifies through anti-inflammatory drugs and partnerships, complementing its broader immunology pipeline amid market growth projected beyond $16 billion by 2032. Chiesi Farmaceutici specializes in specialized inhalers and therapies for severe cases, gaining traction in Europe and emerging markets via innovative delivery systems. These firms drive competition through pipelines targeting eosinophilic COPD and biologics underserved historically by small molecules.
Market leadership hinges on revenue forecasts, M&A activity, and pipeline advancements amid drivers like prevalence increases and biologic shifts. From 2020-2030, top players like GSK and Novartis forecast robust growth via products like depemokimab and Sandoz generics, while acquisitions—such as Sanofi's partnerships and BMS's immunology expansions—signal consolidation. Challenges include pricing pressures and generics, yet opportunities in digital health (e.g., Abbott's Bigfoot integration) and novel modalities like ENaC inhibitors position them for outperformance. Overall, these ten companies control key segments—bronchodilators, monoclonal antibodies, and combinations—fueling a market responsive to R&D and regulatory approvals.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.